

PRANATHARTHI HARAN CHANDRASEKAR, M.D.

ADDRESS

Division of Infectious Diseases
Department of Internal Medicine
Harper Hospital
3990 John R, 5 Hudson, Room 5911
Detroit, Michigan 48201
(313) 745-9649

EDUCATION

1967 Certificate of Education, (Advanced Level), St. Benedict's
College, Colombo, Sri Lanka

1968 Pre-University Certificate, Madurai College, Madurai, India

1973 MBBS, Christian Medical College, Vellore, India

 ECFMG # 0-220-351-1

TRAINING

1974 - 1975 Rotating Intern, Christian Medical College, Vellore, India

1975 Senior House Officer, (Cardiology, Neurology, and
Ophthalmology), Christian Medical College, Vellore, India

1976 Research Fellow, Internal Medicine, Christian Medical College,
Vellore, India

1977 Resident, Department of Psychiatry, Downstate Medical Center,
Brooklyn, NY

1978 - 1980 Resident, Department of Internal Medicine, St. Francis Medical
Center, Trenton, NJ

1980 - 1981 Resident, Department of Internal Medicine, University of
Louisville, Louisville, KY

1981 - 1983 Fellow, Division of Infectious Diseases, Hahnemann University Hospital,
Philadelphia, PA

FACULTY APPOINTMENTS

1996 -Present	Professor, Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI
1989 - 1996	Associate Professor, Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI
1983 - 1989	Assistant Professor, Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI
1985 – Present	Adjunct Assistant Professor, Department of Allied Health Professions and Pharmacy Practice, Wayne State University School of Medicine, Detroit, MI

HOSPITAL OR OTHER PROFESSIONAL APPOINTMENTS

1983 - 1984	Medical Director, Detroit Center for Clinical Studies, Detroit, MI (Pharmakinetics Laboratories, Baltimore, MD)
1983 - 1989	Infection Control Committee, Detroit Receiving Hospital Pharmacy and Therapeutics Committee, Detroit Receiving Hospital
1989 - 1995	Vice-Chairman, Infection Control Committee, Harper Hospital
1989 - 1996	AIDS Task Force, Detroit Medical Center
1993 - 2002	Member, Medical Advisory Committee, Harper Hospital
1993 - Present	Program Director, Infectious Diseases Fellowship Wayne State University
1994 - Present	International Committee on Infections in Transplant Recipients, Immunocompromised Host Society
1997 - Present	Renaissance Home Health Care – Member, Medical Advisory Board
2002 - Present	Pharmacy & Therapeutics Committee DMC, Hematology/Oncology
2002 - Present	Board of Directors, Affiliated Internists, Department of Medicine, Wayne State University

MAJOR PROFESSIONAL SOCIETIES

American College of Physicians, Fellow
Infectious Diseases Society of America, Fellow
American Society of Microbiology, Member
International Immunocompromised Host Society, Member

EXAMINER

Ph. D. - Microbiology, University of Calcutta, India (1990)

INTERNATIONAL PROGRAMS

Coordinator, Symposium on Nosocomial Infections, Christian Medical College and Hospital, Vellore, India, 1992.

Meet-the-Professor Sessions, Annual Meeting of Infectious Diseases Society of America, 1999.

Round Table Session – 12th International Symposium – Immunocompromised Host Society, Bergen, Norway, 2002.

Chair, Asian American International Medical Society. Advances in Medicine for the New Millennium, Goa, India, January 3-5, 2003.

Invited speaker, National Infection Control Society Meeting, Christian Medical College and Hospital, Vellore, India, January 2003.

LICENSURE AND BOARD CERTIFICATION

Licensure - State of Michigan

Diplomate, American Board of Internal Medicine, 1981

Diplomate, Infectious Diseases, American Board of Internal Medicine, 1984

SERVICE

1991	Ad Hoc Advisory Committee on HIV-Infected Health Care Workers, State of Michigan (1991)
1988 – Present	Infectious Diseases Protocols for Bone Marrow Transplant Service
1999	Reviewer – Guidelines for the Prevention of Opportunistic Infections in Bone Marrow Transplant Recipients, Department of Health & Human Services, Centers for Disease Control and Prevention.
2006 -	Chair, Search Committee for the position of Division Chief in Hematology/Oncology

Pranatharthi H. Chandrasekar, M.D.

Curriculum Vitae

Page 4

2007 – Search Committee member for the position of Chairman, Department of Internal Medicine.

REVIEWER

Project Outline Application for Swiss National Science Foundation, 2000-2001

EDITOR

eMedicine, 2000-2001, 2005-2006

Drugs of Today – Editorial Board

Indian Journal of Medical Microbiology

JOURNAL ACTIVITY - REVIEWER

Antimicrobial Agents and Chemotherapy

Biology of Blood and Marrow Transplantation

Bone Marrow Transplantation

Clinical Infectious Diseases

Journal of Antimicrobial Chemotherapy

Archives of Internal Medicine

Cancer

Kidney International

Critical Care Medicine

European Journal of Clinical Infection

Annals of Pharmacotherapy

The National Medical Journal of India

Indian Journal of Medical Microbiology

Journal of Hospital Formulary

Drug Intelligence and Clinical Pharmacy

Journal of Respiratory Diseases

Hospital Physician

Sentinel Reader/McMaster University

AWARDS

Departmental Teaching Award, 1999

Leadership and Teaching Excellence

College Teaching Award, 1999, 2005

Benjamin Pulimood Oration, Christian Medical College, Vellore, 2000

Merck Mycology Award – Immunocompromised Host Society, 2000

Best Doctors in America, 2000, 2001-2002, 2003-2004, 2005-2006.

TEACHING

1983 - Present Wayne State University Faculty

1983 - Present Regular teaching rounds with fellows, house staff and medical students on the Infectious Diseases Consultation Service

1983 - Present Physical Diagnosis for second year medical students

1988 - Present Hematology/Oncology House Staff - Management of Infection in Compromised Hosts - Monthly

PUBLICATIONS

Original observations in Refereed Journals:

1. LeFrock JL, Molavi A, Lentnek A, Rolston KVI, **Chandrasekar PH**, Smith Kennangara DW, Schell RF, Oaks SS, and Carr BB: Comparative study of ceftizoxime and cefamandole in the treatment of bronchopulmonary infections. *J Antimicrobial Chemotherapy*, 10(5):215-221, 1982.
2. LeFrock JL, Molavi A, Rolston KVI, Smith BR, Schell RF, **Chandrasekar PH**, and Carr B: In vitro and in vivo comparison of mezlocillin and cefoxitin. *J Antimicrob Chemother* 11 (Suppl C), 1983.
3. Rolston KVI, **Chandrasekar PH**, Smith BR, and LeFrock JL: Cefmenoxime penetration into cerebrospinal fluid across non-inflamed meninges. *J Antimicrob Chemother* 12:519-521, 1983.
4. Rolston KVI, **Chandrasekar PH**, LeFrock JL, and Schell RF: Activity of ceftazidime, other B-lactams and aminoglycosides against Pseudomonas aeruginosa. *Chemother* 30:31-34, 1984.
5. **Chandrasekar PH**, Rolston KVI, Smith BR, and LeFrock JL: Ceftriaxone penetration into cerebrospinal fluid across inflamed and non-inflamed meninges. *J Antimicrob Chemother* 14:427-430, 1984.
6. **Chandrasekar PH**, Schell RF, Rolston KVI, and Francisco M: Comparative in vitro activities of cefsulodin, B-lactams and aminoglycosides against Pseudomonas aeruginosa. *Chemother* 30:165-169, 1984.
7. **Chandrasekar PH**, Rolston KVI, Chokkavelu V, LeFrock JL, and Kannangara DW: Comparative efficacy of four antibiotics in anaerobic pulmonary infection. *Chemother* 30:331-336, 1984.
8. Chokkavelu V, **Chandrasekar PH**, Rolston KVI, LeFrock JL, and Schell RF: Activity of eleven antimicrobial agents against methicillin, methicillin and rifampin resistant Staphylococcus aureus. *Chemother* 30:97-101, 1984.
9. LeFrock JL, Molavi A, Smith BR, Kannangara DW, Rolston KVI, **Chandrasekar PH**, and Rosenberg M: Comparison of mezlocillin and cefoxitin in use of obstetrical and gynecological infections. *Infections in Surgery* 3:507-512, 1984.
10. LeFrock JL, McCloskey RV, Molavi A, Rosenberg M, Kannangara DW, Rolston KVI, **Chandrasekar PH**, and Chokkavelu V: Cefmenoxime - Clinical, bacteriologic, and pharmacologic studies. *Am J Med* 77:72-78, 1984.

Pranatharthi H. Chandrasekar, M.D.

Curriculum Vitae

Page 6

11. Rolston KVI, **Chandrasekar PH**, and LeFrock JL: Antimicrobial tolerance In group C and group G streptococci. *J Antimicrob Chemother* 13:389-392, 1984.
12. LeFrock JL, Molavi A, Smith BR, Black P, Rosenberg M, Rolston KVI, Brodner R, **Chandrasekar PH**, Henao L, and Kannangara DW. Effectiveness of cefotaxime in Gram-negative meningitis. *Neurosurg* 15:679-682, 1984.
13. **Chandrasekar PH**, Smith B, LeFrock JL, and Carr B: Enterococcal superinfection and colonization with aztreonam therapy. *Antimicrob Agents Chemother* 26:280-282, 1984.
14. **Chandrasekar PH**, Price S, and Levine DP: In vitro evaluation of HR 810, teicoplanin and 4 other antimicrobials against enterococci. *J Antimicrob Chemother* 16:179-182, 1985.
15. Rolston KVI, **Chandrasekar PH**, and LeFrock JL: Clinical features and antimicrobial therapy of infections caused by group G streptococci. *Infection* 12:203-206, 1985.
16. Unowsky J, **Chandrasekar PH**, DeLorenzo W, and Levine DP: The in vitro and in vivo activity of coumermycin and other antibacterial agents against Methicillin-resistant strains of Staphylococcus aureus. *Chemotherapy* 32:499-505, 1986.
17. **Chandrasekar PH**, Kruse JA, and Mathews MF: Nosocomial infections among patients in different types of intensive care units at a city hospital. *Crit Care Med* 14:508-510, 1986.
18. **Chandrasekar PH** and Narula A: Bone and joint infections in intravenous drug abusers. *Rev Inf Dis* 8:904-911, 1986.
19. Hess JA, **Chandrasekar PH**, Mortiere M, and Molinari JA: Comparative efficacy of ketoconazole and mebendazole in experimental trichinosis. *Antimicrobial Agents and Chemotherapy* 30:953-954, 1986.
20. **Chandrasekar PH**, Crane LR, and Bailey EJ: Comparison of the activity of antibiotic combinations in vitro with clinical outcome and resistance emergence in serious infection of Pseudomonas aeruginosa in non-neutropenic patients. *J Antimicrob Chemother* 19:321-329, 1987.
21. LeFrock JL, Smith BR, **Chandrasekar PH**, Rolston KVI, Molavi A, and Kannangara DW: Efficacy and safety of aztreonam in the treatment of serious Gram-negative infections. *Arch Intern Med* 147:325-328, 1987.
22. **Chandrasekar PH**, Levine DP, Price S, and Rybak MJ: Comparative efficacies of imipenem-cilastatin and vancomycin in experimental aortic valve endocarditis due to methicillin resistant Staphylococcus aureus. *J Antimicrob Chemother*, 21:461-469, 1988.
23. **Chandrasekar PH**: Nail discoloration & Human Immunodeficiency Virus (HIV) infection. (Brief Communication). *Am J Med* 86:506-507, 1989.
24. **Chandrasekar PH**, Sluchak JA: Newer Agents Against Methicillin and/or Gentamicin-Resistant and Susceptible Staphylococci. *Chemotherapy* 35:333-337, 1989.

25. **Chandrasekar PH**, Sluchak JA: In Vitro Susceptibility and Emergence of Resistance of Gram-positive Cocci to Paldimycin. *J Antimicrob Chemother* 24:821-824, 1989.
26. **Chandrasekar PH**, Rudnick CA: How to treat HIV-infected patients with cardiovascular problems. *AIDS Medical Report* 2(10) 112-116, 1989.
27. Brown RB, Kruse JA, Counts GC, Russell JA, Christian NV, Sands ML: Endotracheal Tobramycin Study Group. Double-blind study of Endotracheal Tobramycin in the treatment of gram-negative bacterial pneumonia. *Antimicrobial Agents Chemother* 34: 269-272, 1990.
28. **Chandrasekar PH**, Molinari JA, Kruse JA: Risk factors for human immunodeficiencies virus infection among parenteral drug abusers in a low prevalence area. *Southern Medical Journal* 83:996-1001, 1990.
29. Rybak MJ, Albrecht LM, Boike SC, **Chandrasekar PH**: Analysis of Vancomycin Nephrotoxicity. *J Antimicrobial Chemother* 25: 679-687, 1990.
30. **Chandrasekar PH**: Office Management of Apparently Healthy Persons with Human Immunodeficiency Virus Infection. *AIDS Med Report* 3 (10) 115-122, 1990.
31. Poplin EA, Gordon CJ, Piskorowski TJ and **Chandrasekar PH**: Pneumocystis carinii Pneumonia in non-AIDS Patients with Solid Tumors. *CANCER* 68:1931 94, 1991.
32. **Chandrasekar PH**, Cronin SM: Nephrotoxicity in Bone Marrow Transplant Recipients Receiving Aminoglycoside plus Cyclosporine or Aminoglycoside Alone. *Journal of Antimicrobial Chemotherapy* 27: 845-849, 1991.
33. Ahmed AJ, Kruse JA, Haupt MT, **Chandrasekar PH** and Carlson RW: Hemodynamic Response to Gram-Positive versus Gram-Negative Sepsis in Critically III Patients. *Crit Care Med* 19:1520-1525, 1991.
34. **Chandrasekar PH**, Sluchak JA: In Vitro Susceptibility of Cefoperazone Susceptible and Resistant Gram-Negative Rods to Cefoperazone Plus Sulbactam, Other, Aminoglycosides and Quinolones. *Infection* 19: 49-53, 1991.
35. Walsh TJ, Hathorn JW, Sobel JD, Merz WG, Sanchez V, Maret SM, Buckley HR, Pfaller MA, Schaufele R, Sliva C, Navarro E, Leggiones J, **Chandrasekar PH**, Lee J, and Pizzo PA. Detection of Circulating Candida Enolase by Immunoassay in Patients with Cancer and Invasive Candidiasis. *N Engl J Med* 324: 1026-1031, 1991.
36. Goodman JL, Winston DJ, Greenfield RA, **Chandrasekar PH**, Fox B, Kalzer H, Shaddock RK, Shea TC, Stiff P, Friedman DJ, Powderly WG, Silber JL, Horowitz H, Lichtin A, Wolff SN, Mangan KF, Silver SM, Weisdorf D, Ho WG, Gilbert G, and Buel D. Does Fluconazole Prevent Fungal Infections in Patients Undergoing Bone Marrow Transplantation? Results of a Randomized Controlled Trial. *N Engl J Med* 326:845-851, 1992.

37. Knoll-Vlachos S and **Chandrasekar PH**. Adult Leukemia Due to Human Lymphotropic Virus Type-I (HTLV-1): An Increasing Problem. *Primary Care & Cancer*, March 1992.
38. Touchette MA, **Chandrasekar PH**, Milad MA and Edwards DJ. Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man. *British Journal of Clinical Pharmacology*, 34:74-78, 1992.
39. Molinari JA, Cottone JA, **Chandrasekar PH**. Tuberculosis in the 1990's: Current Implications for Dentistry. *Compendium of Continuing Education for Dentistry*. XIV: 276-294, 1993.
40. Winston DJ, **Chandrasekar PH**, Lazarus HM, Goodman JL, Silber JL, Horowitz H, Shadduck RK, Rosenfeld CS, Ho WG, Islan MZ and Buell DN. Fluconazole Prophylaxis of Fungal Infections In Patients with Acute Leukemia: Results of a Placebo-Controlled, Double-Blind, Multicenter Trial. *Annals of Internal Medicine*, 118:495-503, 1993.
41. Shearer C and **Chandrasekar PH**. Cutaneous Alternariosis and Regional Lymphadenitis During Allogeneic Bone Marrow Transplantation. *Bone Marrow Transplantation* 11:497-499, 1993.
42. **Chandrasekar PH**, Sluchak JA, Kruse JA. Therapy with cefoperazone plus sulbactam against disseminated infection due to cefoperazone-resistant Pseudomonas aeruginosa and Escherichia coli in granulocytopenic mice. *Antimicrobial Agents and Chemotherapy*, 37:1927-1930, 1993.
43. **Chandrasekar PH**, Gatny CM, Bone Marrow Transplantation Team. Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients. *Chemotherapy*, 40:136-143, 1994.
44. Gajewski LK, Bailey EM, Brown P, and **Chandrasekar PH**. Determination of the Need for a Prospective DUE of Intravenous Immune Globulin at the Detroit Medical Center. *American Society Hospital Pharmacists*, 51:801-805, 1994.
45. **Chandrasekar PH** and Brown WJ. Clinical Issues of Blood Cultures. *Archives of Internal Medicine* 154:841-849, 1994.
46. **Chandrasekar PH**, Gatny CM, Bone Marrow Transplantation Team. The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients. *J Antimicrob Chemother*, 33:309-318, 1994.
47. Alangaden G, **Chandrasekar PH**, Bailey E, Khaliq Y, Bone Marrow Transplantation Team. Antifungal prophylaxis with fluconazole during bone marrow transplantation. *Bone Marrow Transplantation*, 14:919-924, 1994.
48. Shearer C, **Chandrasekar PH**, Bone Marrow Transplantation Team. Pulmonary Nocardiosis in a BMT patient. *Bone Marrow Transplantation*, 15:479-481, 1995.

49. Momin F, **Chandrasekar PH**. Antimicrobial Prophylaxis in Bone Marrow Transplantation. *Annals of Internal Medicine* 123:205-215, 1995.
50. Naik H, Siddique N, **Chandrasekar PH**. Foscarnet Therapy for Acyclovir-Resistant Herpes Simplex Virus-1 Infection in Allogeneic Bone Marrow Transplantation Recipients. *Clinical Infectious Diseases* 21:1514-1515, 1995.
51. Vazquez JA, Lundstrom TS, Dembry LM, **Chandrasekar PH**, Boikov D, Perri MB, and Zervos MJ. Invasive *Candida guilliermondii* infection: case report, in-vitro susceptibility studies, and molecular analysis. *Bone Marrow Transplantation* 16:849-853, 1995.
52. **Chandrasekar PH**, Weinmann AJ, Shearer C, and Bone Marrow Transplantation Team. Autopsy-identified Infections Among Bone Marrow Transplant Recipients: A Clinico-Pathologic Study of 56 Patients. *Bone Marrow Transplantation* 16:675-681, 1995.
53. Ducharme MP, Slaughter RL, Warbasse LH, **Chandrasekar PH**, Van de Velde V, Mannens G, and Edwards DJ. Itraconazole and Hydroxy-Itraconazole Serum Concentrations are Reduced More than Ten-Fold by Phenytoin. *Clinical Pharmacology and Therapeutics* 58:617-624, 1995.
54. **Chandrasekar PH**, Alangaden G. Newer Betalactam Antibiotics. In *Current Opinion in Infectious Diseases*, Ed. Bodey GP. 9:391-397, 1996.
55. **Chandrasekar PH**, Fairfax M, Nandi P, Crane L. Cutaneous Infections due to *Acanthamoeba* in Patients with AIDS. *Archives of Internal Medicine*. 157:569-572, 1997.
56. **Chandrasekar PH**, Momin F, and BMT Team. Disseminated toxoplasmosis in bone marrow transplantation (BMT). *Bone Marrow Transplantation* (19)7:685-689, 1997.
57. **Chandrasekar PH**. Safety and efficacy of cefoperazone plus sulbactam vs ceftazidime in the empiric treatment of febrile neutropenia. *Journal of Pharmacy Technology*, 14:63-69, 1998.
58. Manavathu, EK, Alangaden GJ, **Chandrasekar PH**. In-vitro isolation and antifungal susceptibility of amphotericin B resistant mutants of *Aspergillus fumigatus*. *Journal of Antimicrobial Chemotherapy* 41:615-619, 1998.
59. Manavathu EK, Dimmock JR, Vashishtha SC, Cutright JL, **Chandrasekar PH**. In-vitro and in-vivo susceptibilities of *Aspergillus fumigatus* to a novel conjugated styryl ketone. *Journal of Antimicrobial Chemotherapy* 42:585-590 1998.
60. Manavathu Ek, Cutright JL, **Chandrasekar PH**. Organism-dependent fungicidal activity of azoles. *Antimicrob Agents Chemother* 42:3018-3021, 1998.
61. **Chandrasekar P H**. Treating Herpes Infections. *Advances in Wound Care*, 12: 254-262, 1999.

62. Abraham OC, Manavathu EK, Cutright JL, **Chandrasekar PH**. In vitro susceptibilities of *Aspergillus* species to voriconazole, itraconazole and amphotericin-B. *Diag Microbiol Infect Dis* 33:7-11, 1999.
63. Manavathu EK, Vazquez JA, **Chandrasekar PH**. Reduced susceptibility of *Aspergillus fumigatus* to Itraconazole due to decreased intracellular accumulation of the antifungal agent. *International Journal of Antimicrobial Agents* 12:213-219, 1999.
64. Manavathu EK, Cutright JL, and **Chandrasekar PH**. A comparative study of the susceptibility of germinated and ungerminated conidia of *Aspergillus fumigatus* to various antifungal agents. *Journal of Clinical Microbiology* 37:858-861, 1999.
65. Ebright JR, **Chandrasekar PH**, Marks S, Fairfax MR, Aneziokoro A, McGinnis MR. Invasive sinusitis and cerebritis due to *Curvularia clavata* in an immunocompetent adult. *Clinical Infectious Diseases* 28:687-689, 1999.
66. Abraham OC and **Chandrasekar PH**. Emergence of antimicrobial-resistant infections in cancer patients. *Indian Journal of Medical Microbiology (In Press)*.
67. Prasad AS, Beck FWJ, Kaplan J, **Chandrasekar PH**, Ortega J, Fitzgerald JT, Swerdlow P. Effect of Zinc Supplementation on Incidence of Infections and Hospital Admissions in Sickle Cell Disease (SCD). *American Journal of Hematology* 61:194-202, 1999.
68. Manavathu EK, Dimmock JR, Vashishtha SC, and **Chandrasekar PH**. Proton Pumping ATPase Targeted Antifungal Activity of a Novel Conjugated Styryl Ketone. *Antimicrobial Agents and Chemotherapy* 43:2950-2959, 1999.
69. Manavathu EK, Nune U, Kanuri K, **Chandrasekar PH**, Abraham OC. Effect of test medium on the in-vitro susceptibility testing results for *Aspergillus fumigatus*. *Rev Iberoam Micol* 17:107-110, 2000.
70. **Chandrasekar PH**, Alangaden G, Manavathu E. *Aspergillus* – A rising problem in tertiary care hospitals? *Clinical Infectious Diseases* 30:984, 2000.
71. **Chandrasekar PH**. Management of fever in neutropenic cancer patients: Review. *Hospital Physician*, February 2000, 37-38.
72. **Chandrasekar PH**, Cutright J, Manavathu E. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea pig model. *The Journal of Antimicrobial Chemotherapy* 45:673-676, 2000.
73. Samuel J, Alangaden G, and **Chandrasekar PH**. Cervical adenitis due to *Mycobacterium fortuitum* in a patient with AIDS. *Infectious Diseases in Clinical Practice* 9:221-222, 2000.

74. McNeil SA, Clark NM, **Chandrasekar PH** and Kauffman CA. Successful Treatment of Vancomycin-Resistant *Enterococcus faecium* bacteremia with Linezolid after failure of treatment with Synercid (Quinupristin/Dalfopristin). *Clinical Infectious Diseases* 30:403-404, 2000.
75. Manavathu E, Cutright J, **Chandrasekar PH**. A Comparative Study of the In Vitro Susceptibilities of Clinical and Laboratory-Selected Resistant Isolates of *Aspergillus* Species to Amphotericin B, Itraconazole, Voriconazole and SCH 56592. *Journal of Antimicrobial Chemotherapy* 46:229-234, 2000.
76. **Chandrasekar PH**, Arnow PM. Cefepime versus Ceftazidime as Empiric Therapy for Fever in Neutropenic Patients with Cancer. *Annals of Pharmacotherapy* 34:989-995, 2000.
77. Prasad AS, Fitzgerald JT, Bao B, Beck FWJ, **Chandrasekar PH**. Duration of Symptoms and Plasma Cytokine Levels in Patients with the Common Cold Treated with Zinc Acetate. *Annals of Internal Medicine* 133: 245-252, 2000.
78. Kanno M, **Chandrasekar PH**, Bentley G, Vander Heide RS, and Alangaden GJ. Disseminated Cytomegalovirus Disease in Non-Conventional Hosts (Non-AIDS/Non-Transplant Patients). *Clinical Infectious Diseases* 32:313-316, 2001.
79. Bhargava P, **Chandrasekar PH**. Serious Fungal Infections: Review. *Hospital Physician* 37:27-28, 2001.
80. **Chandrasekar PH**, Abraham OC, Klein J, Alangaden GJ, Chalasani G, Cassells L, Dansey R, Abella S, Karanes C, Peters W, Baynes R. Low Infectious Morbidity Following Intensive Chemotherapy and Autologous Peripheral Blood Progenitor Cell Transplantation in the Outpatient Setting for Women with Breast Cancer. *Clinical Infectious Diseases* 32:546-551, 2000.
81. Manavathu EK, Dimmock JR, Vashishtha SC and **Chandrasekar PH**. Inhibition of H⁺ - ATPase mediated proton pumping in *Cryptococcus neoformans* by a novel conjugated styryl ketone. *Journal of Antimicrobial Chemotherapy*. 47: 491-494 .
82. **Chandrasekar PH**, Manavathu EK. Voriconazole: A Second Generation Triazole. *Drugs of Today* 37(2):135-148, 2001.
83. **Chandrasekar PH**, Cutright JL, Manavathu EK. *Aspergillus*: Rising frequency of clinical isolation and continued susceptibility to antifungal agents, 1994-1999. *Diagn Microbiol Infect Dis* 41:211-214, 2001.
84. Moosa MYS, Alangaden GJ, Manavathu EK, and **Chandrasekar PH**. Resistance of Amphotericin B does not emerge during treatment for invasive aspergillosis. *J Antimicrob Chemother* 49:209-213, 2002.
85. Soubani AO, **Chandrasekar PH**. The clinical spectrum of pulmonary aspergillosis. *Chest* 121:1988-1999, 2002.

86. Bowden R, **Chandrasekar PH**, White MH, Li X, Pietrilli L, Gurwith M, Van Burik J, Laverdiere M, Safrin S and Wingard JR. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion (ABCD) vs amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. *Clin Infect Dis* 35:359-366, 2002.
87. Pulimood S, Ganesan L, Alangaden G and **Chandrasekar PH**. Polymicrobial Candidemia. *Diagn Microbiol Infect Dis* 44:353-357, 2002
88. Alangaden GJ, Wahiduzzaman M, **Chandrasekar PH**, and the BMT Group. Aspergillosis: Most common serious community acquired pneumonia in allogeneic stem cell transplant recipients with graft-versus-host disease. Significance of gram-negative bacilli as co-pathogens. *Clin Infect Dis* 35:659-664, 2002.
89. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Ostemann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, **Chandrasekar PH**, Hodges MR, Schlamm HT, Troke PF, De Pauw B, for the Invasive Fungal Infection Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. *New Engl J Med* 347:408-415, 2002.
90. **Chandrasekar PH**, Manavathu EK, Caspofungin. *Drugs of Today* 38:829-846, 2002.
91. Winston DJ, Yeager AM, **Chandrasekar PH**, Snyderman DR et al. Randomized Comparison of Oral Valacyclovir and Intravenous Ganciclovir for Prevention of Cytomegalovirus Disease after Allogeneic Bone Marrow Transplantation. *Clin Infect Dis* 36:749-758, 2003.
92. Winston DJ, Maziarz RT, **Chandrasekar PH**, Lazarus HM, et al. A Multicenter Randomized Trial of Intravenous Itraconazole vs IV/PO fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients. *Ann Intern Med* 138:705-713, 2003.
93. **Chandrasekar PH**. Autologous stem cell transplantation in the outpatient setting: Feasible or Not? <http://www.siicsalud.com/dato/dat 031/03203000.htm> June 2003.
94. **Chandrasekar PH**, Transplante Autologo De Precursores Hematopoyeticos En El Ambito De La Medicina Ambulatoria. www.siicsalud.com 2003.
95. Manavathu EK, Ramesh MS, Baskaran I, Ganesan LT, **Chandrasekar PH**. A Comparative Study of the Post Antifungal Effect (PAFE) of Amphotericin B, Triazoles, and Echinocandins on *Aspergillus fumigatus* and *Candida albicans*. *J Antimicrob Chemother.* 53:386-389, 2004.
96. Varanasi NL, Baskaran I, Alangaden GJ, **Chandrasekar PH** and Manavathu EK. Novel Effect of Voriconazole on Conidiation of Aspergillus species. *Int J Antimicrob Agents* 23:72-79, 2004.

97. Alangaden GJ, Brown W, and **Chandrasekar PH**. Recognition of Misdiagnosed Tuberculosis in a BMT Recipient Leads to Identification of "Pseudo-tuberculosis" due to laboratory contamination. *Inf Dis Clin Practice* 12:328-333, 2004.
98. Ganesan LT, Manavathu EK, Cutright JL, Alangaden GJ, **Chandrasekar PH**. In vitro Activity of Nikkomycin Z Alone and in Combination with Polyenes, Triazoles or Echinocandins Against *Aspergillus fumigatus*. *Clin. Microbiol. Infection*. 10:961-966, 2004.
99. Wadei H, Alangaden GJ, Sillix DH, El-Amm JM, Gruber S, West MS, Granger DK, Garnick J, **Chandrasekar PH**, Migdal SD and Haririan A. West Nile Virus Encephalitis: An Emerging Disease in Renal Transplant Recipients. *Clin Transpl*. 18:753-758, 2004.
100. **Chandrasekar PH**, Cutright JL, Manavathu E. Efficacy of Voriconazole Plus Amphotericin B/Micafungin in a Guinea Pig Model of Invasive Pulmonary Aspergillosis. *Clinical Microbiology and Infection*. 10:925-928, 2004.
101. Manavathu EK, Curtright JL, and **Chandrasekar PH**. In vivo Resistance of a Laboratory-Selected *Aspergillus fumigatus* Isolate to Amphotericin B. *Antimicrob Agents Chemother*.49;(1):428-430, 2005.
102. **Chandrasekar PH**. Antifungal Resistance in *Aspergillus*. *Medical Mycology* 43 (Suppl 1) S295-S298, 2005.
103. **Chandrasekar PH**. Riches Usher Dilemmas – Antifungal Therapy in Aspergillosis. *Biology of Blood and Marrow Transplantation* 11:(2) 77-84, 2005.
104. **Chandrasekar PH**. Real Time PCR for early detection of toxoplasmosis in hematopoietic stem cell recipients. Ready for Prime Time? *Clin Infect Dis*. 40: 79-81, 2005.
105. Gruber SA, Garnick J, Morawski K, Sillix DH, West MS, Granger DK, El-Amm JM, Alangaden GJ, **Chandrasekar PH**, Haririan A. Cytomegalovirus Prophylaxis with valganciclovir in African-American renal Allograft recipients based on Donor/Recipient Serostatus. *Clin Transplantation* 19: (2): 273-278, 2005
106. **Chandrasekar PH** and Ito JI. Amphotericin B Lipid Complex in the Management of Invasive Aspergillosis in Immunocompromised Patients: Analysis of the CLEAR® Database. *Clin Infect Dis* 40; Suppl 6:S392-400, 2005.
107. Krishnan S, Manavathu EK, **Chandrasekar PH**. A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of *Aspergillus fumigatus*. *J. Antimicrob Chemother* 55: 914-920, 2005.
108. Ito JI, **Chandrasekar PH**, Hooshmand-Rad R. Effectiveness of Amphotericin B Lipid Complex (ABLC) Treatment in Allogeneic Hematopoietic Cell transplant (HCT) Recipients with Invasive Aspergillosis (IA). *Bone Marrow Transplant* 36:873-7, 2005.

Pranatharthi H. Chandrasekar, M.D.

Curriculum Vitae

Page 14

109. **Chandrasekar PH.** Antifungal resistance in *Aspergillus*. *Med Mycol.* 2005 May;43 Suppl 1:S295-8. Review.
110. **Chandrasekar PH,** Ito JL. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. *Clin Infect Dis.* 2005. May 1;40 Suppl 6:S392-400.
111. **Chandrasekar PH,** Sobel J. Micafungin: A New Echinocandin. *Clin Infect Dis* 42:1171-8, 2006.
112. Alangaden GJ, Thyagarajan R, Gruber SA, Morawski K, Garnick J, el-Amm JM, West MS, Sillix DH, **Chandrasekar PH,** Haririan A. Infectious complications after kidney transplantation: current epidemiology and associated risk factors. *Clin Transplant.* 20;(4):401-9, 2006.
113. **Chandrasekar P.** The experience is CLEAR. *Int J Antimicrob Agents.* 27 ; Suppl 1 :31-5, 2006.
114. **Chandrasekar P.** Selection criteria for antifungals : The right patients and the right reasons. *Int J. Antimicrob Agents.* 27; Suppl 1:17-20, 2006.
115. Anaissie EJ, Segal BH, Graybill JR, Arndt C, Perfect JR, Kleinberg M, Pappas P, Benjamin D, Rubin R, Aberg JA, Adderson EE, Adler-Shohet FC, Akan H, Akova M, Almyroudis NG, Alexander BD, Andes D, Arrieta A, Baddley JW, Barron MA, Belzberg H, Boucher HW, Boyce TG, Casadevall A, **Chandrasekar PH,** et al.. Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. *Clin Infect Dis.* 2006 Oct 15;43 (8):1031-9. Epub 2006 Sep 13.
116. Narreddy S, Mellon-Reppen S, Abidi MH, Klein JL, Peres E, Heilbrun L, Smith D, Alangaden G, **Chandrasekar PH.** Opportunistic Infections in Non-myeloblastic stem cell transplant recipients. *Transpl Infect Dis (In Press).*
117. **Chandrasekar PH.** Early Use of Polyenes in Systemic Fungal Infections. *Inf Medicine* 23(10S):3-11, 2006
118. Walsh TJ, Raad I, Patterson TF, **Chandrasekar P,** Donowitz GR, Graybill R, Greene RE., et al. Invasive Aspergillosis with Posaconazole in Patients who are Refractory to or intolerant of conventional therapy: Ext Controlled Trial. *Clin Infect Dis.* 44:2-12, 2007.
119. Afonso NM, Gunasena S, Galla K, Podzorski R, **Chandrasekar PH,** Alangaden GJ. Appropriate Use of Polymerase Chain Reaction for Detection of Herpes Simplex Virus -2 in Cerebrospinal Fluid of Patients at an Inner-City Hospital. *Diagn Microbiol Infect Dis (In Press).*
120. Haririan A, Morawski K, West MS, El-Amm JM, Doshi MD, Cincotta E, Alangaden GJ, **Chandrasekar PH,** Gruber SA. Sirolimus Exposure During the Early Posttransplant Period Reduces the Risk of CMV Infection Relative to Tacrolimus in Renal Allograft Recipients. *Clin Transplant (In Press).*

121. Ullmann AJ, Lipton JH, Vesole D, **Chandrasekar PH**, Langston A, Tarontolo SR et al. Posaconazole versus Fluconazole for Prophylaxis in Graft-versus-Host Disease. *N Engl J Med* 356; (4):335-411, 2007.
122. **Chandrasekar PH**, Increased Dose of Echinocandin for Invasive Fungal Infections: Bonanza for the Patient or the Pharmaceutical Industry ?, *Bone Marrow Transplant* (In Press).
123. Krishnan S, Manavathu EK, **Chandrasekar PH**. *Aspergillus flavus*: the emerging Non-fumigatus *Aspergillus* Species of Significance and a Review of the Literature. *Mycoses* (In Press).

Multicenter Study Participant:

1. Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK, Thompson SE, Sugar AM, Tuazon CU, Fisher JR, Hyslop N, Jacobson JM, Hefner R, Dismukes WE, and the NIAID Mycoses Study Group and the AIDS Clinical Trials Group: Comparison of Amphotericin B with Fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. *N Engl J Med* 326:83-89, 1992.
2. Greenman RL, Schein R, Martin MA, Wenzel RP, Macintyre NR, Emmanuel G, Chmel H, Kohler RB, McCarthy M, Plouffe J, Russell JA and the XOMA sepsis Study Group. A Controlled Clinical Trial of E5 Murine Monoclonal IgM Antibody to Endotoxin in the Treatment of Gram-Negative Sepsis. *J Am Med Association* 266:1097-1102, 1991.
3. Bone RC, Balk RA, Fein AM, Perl TM, Wenzel RP, Reines HD, Quenzer RW, Iberti TJ, Macintyre N, Schien RMH, The E5 Sepsis Study Group. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial. *Critical Care Medicine*, 23:994-1005, 1995.
4. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. *New Engl J Med* 346:225-234, 2002.
5. Lipsky BA, Itani K, Norden C, and the Linezolid Diabetic Foot Infections Study Group. Treating Foot Infections in Diabetic Patients: A Randomized, Multicenter, Open-label trail of Linezolid versus Ampicillin-Sulbactam/Amoxicillin-Clavulanate. *Clin Infect Dis*. 38:17-24, 2004.
6. OA Cornely, J Maertens, DJ Winston, J Perfect, AJ Ullmann, TJ Walsh et al. Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia. *N Engl J of Med* 356:348-359, 2007.

Letters to the Editor:

1. **Chandrasekar PH**, Rybak MJ, and Frankowski JJ: WBC count and vancomycin Letter to the Editor. *Am J Med* 81:1114, 1986.
2. **Chandrasekar PH**: Intravenous Immunoglobulin in Gram-Negative Bacteremia. Letter to the Editor. *Ann Int Med.* 113:877, 1990.
3. **Chandrasekar PH**: "Cure" of chronic cryptosporidiosis during treatment with azidothymidine (AZT) in a patient with AIDS - Letter to the Editor. *Am J Med* 83:187, 1987.
4. Harvey R and **Chandrasekar PH**. Chronic meningitis caused by listeria in a HIV infected patient. Letter to the Editor. *J Infect Dis*, May, 1988.
5. **Chandrasekar PH**, Cushing R. Captopril and Glomerulitis. *Ann Intern Med* 112:550, 1990.
6. **Chandrasekar PH**. Low-Back Pain and Intravenous Drug Abusers. *Arch Int Med* 150: 1125-1128, 1990.
7. **Chandrasekar PH**. Quinolone Prophylaxis During Neutropenia. *Ann Intern Med* 115:833, 1991.
8. **Chandrasekar PH**. Use of Vancomycin in Central Venous Catheter-Related Infections. *Bone Marrow Transplantation* 17:299, 1996.
9. **Chandrasekar PH**. Empiric Antifungal Therapy for Persistent Fever in Neutropenic Patients. *Clinical Infectious Diseases* 32:320-321, 2001.
10. Ibrahim R, Abella S, **Chandrasekar PH**. Tacrolimus-Clarithromycin interaction in a bone marrow transplant patient. *Annals of Pharmacotherapy.* 36: 1971-1972, 2002.
11. Vishnubhotla P, Ibrahim R, **Chandrasekar PH**. Fever and Eosinophilia Associated with Voriconazole Therapy. *Annals of Pharmacotherapy*, 38:900-901, 2004.

Review Articles:

1. **Chandrasekar PH** and Pulimood BM: Miliary tuberculosis. *Christian Medical College and Hospital Alumni Journal*, 1976.
2. **Chandrasekar PH**, Rolston KVI, Kannagara DW, LeFrock JL, and Binnick SA: Hot tub associated dermatitis due to *Pseudomonas aeruginosa*: case reports and review of the literature. *Arch Dermatol* 120:1337-1340, 1984.
3. **Chandrasekar PH** and LeFrock JL: Treatment of anaerobic CNS infections. *Indian J Pathol Microbiol*, 1985.

Review Articles (continued)

4. **Chandrasekar PH** and Molinari JA: Endogenous anaerobes in orofacial infections. *Infections in Surgery* 5:217-224, 1986.
5. **Chandrasekar PH**, Arathoon E, and Levine DP: Infections due to Achromobacter xylosoxidans. *Infections* 14:279-282, 1986.
6. Komshian SV, **Chandrasekar PH**, and Levine DP: Adenovirus pneumonia in healthy adults. *Heart & Lung* 1 6:146-150, 1987.
7. Butler S, Molinari JA, Plezia RA, **Chandrasekar PH**, and Venkat H: Condyloma acuminatum in the oral cavity: four case reports and review of the literature. *Rev Inf Dis* 10:344-350, 1988.
8. Randich CA, **Chandrasekar PH**. An Update on Antibiotics: Part 1. *Hospital Physician* 33(1):19-30, 1997.
9. **Chandrasekar PH**, Randich CA. An Update on Antibiotics: Part II. *Hospital Physician* 33(2):42-48, 1997.
10. **Chandrasekar PH**, Manavathu EK. Caspofungin. *Drugs of Today* 38(12):829-846, 2002.

Books and Chapters:

1. Molinari JA and **Chandrasekar PH**: Mycobacteria, *Essential Dental Microbiology*, Appleton-Century-Croft, New York, Willett and White Publications Ltd., 1990.
2. Molinari JA and **Chandrasekar PH**: Neisseria, *Essential Dental Microbiology*, Appleton-Century-Croft, New York, Willett and White Publications Ltd., 1990.
3. **Chandrasekar PH**: Chapter on Skeletal Infections in Intravenous Drug Abusers. In: Infections in Intravenous Drug Abusers. DP Levine and JD Sobel (Editors), Oxford University Press, New York, NY, pp 306-326, 1991.
4. **Chandrasekar PH**: Chapter on Infections in Non-Granulocytopenic Cancer Patients. In: The Principles and Practice of Medical Intensive Care. RW Carlson and MA Geheb (Editors), WB Saunders Co., Philadelphia, PA, 1993.

Books and Chapters (continued)

5. Molinari JA and **Chandrasekar PH**: Chapter on Re-emergence of Mycobacterium tuberculosis infection as a major occupational risk for health professionals. In: Oral Manifestations of HIV Infection. John Greenspan and Deborah Greenspan (Editors), Quintessence Publishing Co., Chicago, Illinois, 1995.
6. **Chandrasekar PH**. Chapter: Infections in Bone Marrow Transplant Patients (BMT). In: Saunders Manual of Critical Care. W.B. Saunders Co., Philadelphia, PA, p.365, 2002.
7. **Chandrasekar, PH**. Chapter: Herpes Infections. In: Saunders Manual of Critical Care. W.B. Saunders Co., Philadelphia, PA, p. 350, 2002.
8. Kak V, **Chandrasekar PH**. Bone and Joint Infections in Intravenous Drug Abusers. Infections in Injection Drug Users. *Inf Dis Clin N America*, September 2002.
9. **Chandrasekar PH**. Fungi – Other than Candida and Aspergillus: Management of Infections in Oncology Patients. Edited by Wingard JR, and Bowden RA. Martin Dunitz (Taylor & Francis Group) London & New York. P. 203-221, 2003
10. **Chandrasekar PH** (Editor). Chapters on: Bone infections – Author: Alangaden GJ. Joint Infections – Author: Krishnan S. *A Handbook on Infectious Diseases* (In Press).
11. **Chandrasekar PH** and Manavathu EK. Antifungal Resistance – Aspergillus. *Antimicrobial Resistance*. Edited by Sobel J. and Lerner SA.
12. Alangaden GJ, **Chandrasekar PH**. *Cumitech – Infections in Renal/Pancreas/Intestinal Transplant Recipients* (in Press).

Educational Material:

1. Photograph of Hot Tub Dermatitis. In: *Microbiology, Fifth Edition*, Editors Wistreich GA and Lechtman MD. Macmillan Publishing Corp., New York 1988.
2. Audiotape on "The HIV Positive Patient" for Academy of General Dentistry, 1988.
3. A guidebook on antibiotics, Division of Infectious Diseases, published by Department of Internal Medicine, Wayne State University, 1987 - updated 1989.
4. Scientific Exhibit - Comparative In Vitro Activity of Cefoperazone/ Sulbactam, Betalactams, Aminoglycosides & Quinolone Against Susceptible and Resistant Gram-negative Rods. 89th Annual Meeting of the American Society for Microbiology, New Orleans, Louisiana, May, 1989.

Educational Material: (continued)

5. Scientific Exhibit - Reduction of Candidal Colonization with Fluconazole In Neutropenic Cancer Patients. American Society for Hospital Pharmacists, Annual Meeting, Washington, D.C., June, 1992.
6. Brochure - Osteogenic Sarcoma and Adolescent Varicella - A Case Study, published September 1993, Burroughs Wellcome Co.
7. Brochure - Autologous Bone Marrow Transplantation (BMT) and HSV-1 Reactivation - A Case Study, published September 1993, Burroughs Wellcome Co.
8. Audiotape on "Tuberculosis" for the Academy of General Dentistry, 1994.
9. A primer on Aspergillus- CD-Rom. Wayne State University CME Program.
10. Exploring a Paradigm for the Prevention and Treatment of Aspergillosis Monograph. CME: Maryland State Medical Society, 2004.
11. Managing Infections in Hematological Malignancies: Risk Adjusted Approaches. Rising threat of MRSA in the Seriously Ill Patient. Academy for Health Care Education: CME CD-Rom, 2004 (Attached to Blood (Dec 2004) & Clin Inf Dis. (Dec 2004)
12. Knowing your Antifungal Agents: A Primer for Hematology/Oncology Clinicians. Medical College of Wisconsin. CME Program 2006.
13. WSU CME. Invasive Fungal Infection in a Lung Transplant Recipient, 2006.
14. WSU CME. Invasive Fungal Infection in a Pediatric Patient with Leukemia, 2006.
15. WSU CME. Invasive Fungal Infection in a patient with Chronic Lymphatic Leukemia, 2006.
16. WSU CME. Zygomycosis in a Stem Cell Transplant Patient, 2006.
17. Mycosis from Marijuana Diagnosed by PCR. www.frontlinefungus.org, 2006.
18. WSU CME. Ocular Infection in an Orthotopic Liver Transplant Recipient, 2007.
19. Am Acad of CME. Handout: Serious Fungal Infections: New Strategies to Optimize Treatment Outcomes AACME, 2006.

Case Reports:

1. Gutschi LM and **Chandrasekar PH**: Sciatic nerve damage with pentamidine administration - letter to the editor. *Drug Intelligence and Clin Pharmacy* 19:762, 1985.
2. **Chandrasekar PH** and Molinari JA: Oral candidiasis - fore runner of AIDS? *Oral Surg Oral Pathol* 60:532-534, 1985.
3. Kiel RJ, **Chandrasekar PH**, and Levine DP: Unusual complications of Hickman catheter use. *Infections in Surg* 5:465-466, 1986.
4. **Chandrasekar PH**, Kannangara DW, LeFrock JL, and Rolston KVI: Medical treatment of brain abscess with metronidazole. *Infections in Surgery* 927-930, December 1983.
5. **Chandrasekar PH** and Molinari JA: Corynebacterium hemolyticum bacteremia with fatal neurologic complications in an intravenous drug addict. *Am J Med* 82:638-640, 1987.
6. Rybak MJ, Bowles SK, **Chandrasekar PH**, and Edwards DJ: Increased theophylline concentrations secondary to ciprofloxacin. *Drug Intelligence and Clinical Pharmacy* 21:879-881, 1987.
7. Pilla A, Rybak MJ, and **Chandrasekar PH**: Spiramycin in the treatment of cryptosporidiosis. *Pharmacotherapy* 7:188-190, 1987.
8. **Chandrasekar PH**, Molinari JA, Jelinek MT: Polymicrobial anaerobic bacteremia following urethral instrumentation. *Infections in Urology* March/April 4753,1990.
9. Bazzi MN, **Chandrasekar PH**: Fever and Supraclavicular Mass in a Young Man. An Infrequently Identified Etiology. *Hosp Practice* March 15, pp. 94-102, 1991.
10. **Chandrasekar PH**: Extrapulmonary Pneumocystosis. *AIDS Reader* 2 (3): 94-98, 1992.
11. **Chandrasekar PH**: Sore Throat and Hoarseness in a Patient Undergoing Bone Marrow Transplantation. *Primary Care and Cancer* 14:54-56, 1994.
12. **Chandrasekar PH**. Lower Extremity Rash in a Healthy Woman. *Infectious Diseases in Clinical Practice* 3:43, 1994.
13. Naik H, **Chandrasekar PH**. Herpes Simplex Virus (HSV) Colitis in a BMT Recipient. *Bone Marrow Transplantation* 17:285-286, 1996.
14. Lundstrom TS, Fairfax MR, Dugan MC, Vazquez JA, **Chandrasekar PH**, Abella E, and Kasten-Sportes C. *Phialophora verrucosa* infection in a BMT patient. *Bone Marrow Transplantation* 20:789-791, 1997.

Case Reports (continued)

15. Ramnath N, Momin F, Karanes C, Lundstrom T, **Chandrasekar PH**. Fatal mucormycosis (zygomycosis) after intravascular catheterization in a transplant recipient. *Infections in Medicine* 15:252-255, 1998.
16. **Chandrasekar PH**, Alangaden G, An T. Herpes-associated Erythema multiforme. *Infectious Diseases in Clinical Practice* 7:295-297, 1998.
17. Villanueva, A., **Chandrasekar, P.H.** Parvovirus B19 infection presenting as aplasia and pain crisis in a patient with sickle cell disease. *Hospital Physician* June, 1999 pp. 64-71.
18. Mahesh S, Madan S. **Chandrasekar PH**. Zygomycosis following nasogastric tube placement in a cancer patient. *Infect. Med.* 22: 40-42a, 2005.
19. Krishnan S, Barger G, **Chandrasekar PH**. Recurrent strongyloidiasis stercoralis hyperinfection syndrome: Case Report and a Brief Review. *Inf Dis Clin Pract* 14(4):240-243, 2006.
20. Buhari M, **Chandrasekar PH**. CNS Blastomycosis Presenting as Multiple Cerebral Lesions in an HIV-Seronegative homeless man. *Infect Med* (In Press).

Editorial:

1. **Chandrasekar PH** and Pulimood BM: Tuberculosis of colon--common or uncommon? *J Assoc Physicians of India*, September, 1976.
2. **Chandrasekar PH** and Pulimood BM: Gas cysts of the intestine. *J Assoc Physicians of India*, November, 1976.

Book Review:

1. Physician's 1992 Drug Handbook. Springhouse Corporation, Springhouse, Pennsylvania. In *The Journal of Pharmacy Technology* 8:149-150, 1992.
2. *The Year in Infection*, Volume 2. 2005 Clinical Publishing, Oxford, UK. *Clin Infect Dis.* 41:1369, 2005.

PUBLISHED ABSTRACTS

1. A comparative study of liver function tests in cirrhosis and tuberculosis of the Indian Society of Gastroenterology. India, 1976.
2. LeFrock JL, Molavi A, Rolston KVI, **Chandrasekar PH**, Smith B, Kannangara DW, and Lentanek A: Comparative study of ceftizoxime and cefamandole in the treatment of bronchopulmonary infections. A Review of newer cephalosporins. The role of ceftizoxime. Bermuda 1981.
3. **Chandrasekar PH**, Francisco M, and LeFrock JL: In vitro comparison of cefsulodin, other cephalosporins and newer penicillins against P. aeruginosa. 82nd Meeting of American Society for Microbiology, Atlanta, Georgia 1982.
4. Molavi A, LeFrock JL, Rolston K, Smith B, Schell R, Carr B, **Chandrasekar PH**, Lentnek A, and Oaks S: Comparison of mezlocillin and cefoxitin. In: Proceedings of the 2nd International Symposium on Acylureidopenicillins. Reeves DS and Weuta H (ads) London. Excerpta Medica Amsterdam 106-115, 1982.
5. Molavi A, LeFrock JL, Rolston K, **Chandrasekar PH**, Henao L, Kannangara DW, Carr B, Schell R, and Oaks S: Clinical and microbiological evaluation of cefmenoxime. 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Miami Beach, Florida, October 1982.
6. LeFrock J, Molavi A, Rolston K, Smith B, Schell R, Carr B, Oaks S, Kannangara DW, **Chandrasekar PH**, and Lentnek A: Comparative clinical evaluation of meziocillin and cefoxitin in intraabdominal and pelvic infections. 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Miami Beach, Florida, October 1982.
7. Rolston K, **Chandrasekar PH**, and Chokkavelu V: In vitro activity of various antimicrobials against methicillin resistant Staphylococcus aureus. 83rd Meeting of American Society for Microbiology. New Orleans, LA, March 1983.
8. **Chandrasekar PH**, Kannangara DW, Rolston K, and Chokkavelu V: Comparative efficacy of four antibiotics in experimental anaerobic lung abscess in rabbits. 83rd Meeting of American Society for Microbiology. New Orleans, LA, March 1983.
9. **Chandrasekar PH**, Kannangara DW, and Chokkavelu V: In vitro activity of beta-lactams and aztreonam against gentamicin susceptible and resistant P. aeruginosa. 83rd Meeting of American Society for Microbiology. New Orleans, LA, March 1983.
10. Rolston K, **Chandrasekar PH**, Smith BR, LeFrock JL: Cefmenoxime penetration into cerebrospinal fluid across non-inflamed meninges. American College of Clinical Pharmacology. Washington, D.C., April 1983.

PUBLISHED ABSTRACTS: (continued):

11. **Chandrasekar PH**, Rolston K, Smith BR, and LeFrock JL: Penetration of ceftriaxone into human cerebrospinal fluid. American College of Clinical Pharmacology. Washington, D.C., April 1983.
12. LeFrock JL, Molavi A, McCloskey R, Rolston K, **Chandrasekar PH**, Smith BR, Kannangara DW, Carr B, and Rosenberg M: Cefmenoxime therapy of skin and skin structure infections. 13th International Congress of Chemotherapy, Vienna Austria, 1983. Abstract to be published in Proceedings of the 13th International Congress of Chemotherapy.
13. LeFrock JL, Molavi A, Smith B, Rosenberg M, Rolston K, **Chandrasekar PH**, and Kannangara DW: Cefotaxime therapy for the treatment of gram-negative meningitis. 13th International Congress of Chemotherapy, Vienna, Austria, 1983. Abstract to be published in Proceedings of the 13th International Congress of Chemotherapy.
14. LeFrock JL, Molavi A, Carr B, Rolston K, Schell R, **Chandrasekar PH**, Kannangara DW: Meziocillin versus cefoxitin in intraabdominal and pelvic infections. 13th International Congress, Vienna, Austria, 1983.
15. Smith B, Rolston K, **Chandrasekar PH**, and LeFrock JL: Penetration of cefmenoxime into bile, cerebrospinal fluid, sputum, and other sites. American College of Clinical Pharmacy Meeting, Washington, 1983.
16. Rolston K, **Chandrasekar PH**, Chokkavelu V, and LeFrock JL: In vitro activity of B-lactams and aminoglycosides against Pseudomonas aeruginosa. 21st Annual Meeting, Association for Gnotobiotics, Baltimore, June 1983.
17. Chokkavelu V, **Chandrasekar PH**, Rolston K, and LeFrock JL: Activity of various antimicrobials against methicillin-resistant Staphylococcus aureus. 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Las Vegas, NV, October 1983.
18. **Chandrasekar PH**, Kannangara DW, Chokkavelu V, and LeFrock JL: Efficacy of ketoconazole and mebendazole in trichinosis in mice. 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Las Vegas, NV, October 1983.
19. **Chandrasekar PH**, Rolston KVI, Kannangara DW, LeFrock JL, and Binnick SA: Hot tub associated Pseudomonas folliculitis. Regional Meeting, American College of Physicians, Eastern and Western Pennsylvania and West Virginia, October 1983.
20. Rolston KVI, **Chandrasekar PH**, Chokkavelu V, and LeFrock JL: Group G streptococcal infections in man, Regional Meeting, American College of Physicians, Eastern and Western Pennsylvania and West Virginia, October 1983.

PUBLISHED ABSTRACTS: (continued)

21. **Chandrasekar PH**, Levine DP, and Stewart M: Bone and joint infections among intravenous drug users in Detroit. 83rd Meeting of American Society for Microbiology, St. Louis, MO, 1984.
22. Sunstrum J, **Chandrasekar PH**, Levine DP, and Rolston K: Group G streptococcal bacteremia: a comparative study. 83rd Meeting of American Society for Microbiology, St. Louis, MO, 1984.
23. Rolston K and **Chandrasekar PH**: Antimicrobial tolerance in group G and group C streptococci. 83rd Meeting of American Society for Microbiology, St. Louis, MO, 1984.
24. Unowsky J, **Chandrasekar PH**, DeLorenzo W, and Levine DP: In vitro and In vivo activity of coumermycin, fusidic acid, cotrimoxazole and vancomycin against methicillin resistant Staphylococcus aureus (MRSA) isolated in Detroit. 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, October 1984.
25. Zervos M, Levine D, Frank R, and **Chandrasekar PH**: Mycotic aneurysms in intravenous drug users in the Wayne State University-Detroit Medical Center. 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, October 1984.
26. Arathoon E, **Chandrasekar PH**, and Levine D: Bacteremic pneumonia with Achromobacter xylosoxidans: Case report and review of literature. Regional Meeting, American College of Physicians, Michigan Chapter, Harbor Springs, MI, October 1984.
27. **Chandrasekar PH**, Palchaudhuri S, Pappas K, Svinarich D, and Levine DP: Mechanism of piperacillin resistance in E. coli at the Detroit Receiving Hospital. 84th Meeting of American Society for Microbiology, Las Vegas, NV, March 1985.
28. Mortiere M, **Chandrasekar PH**, Hess J, and Molinari JA: Comparative efficacy of ketoconazole and mebendazole in experimental trichinosis. 84th Meeting of American Society for Microbiology, Las Vegas, NV, March 1985.
29. **Chandrasekar PH** and Mathews MF: Infections in different types of intensive care units in an acute care hospital. 14th Annual Educational & Scientific Symposium of the Society of Critical Care Medicine, Chicago, IL, May 1985.
30. **Chandrasekar PH** and Chua D: Fungal infections in patients with acquired immune deficiency syndrome (AIDS). 6th International Meeting, International Society for STD Research, London, U.K., August 1985.
31. **Chandrasekar PH**, Hess JA, Mortiere M, and Molinari JM: Treatment of experimental trichinosis with ketoconazole and mebendazole. 25th Interscience Conference on Antimicrobial Agents and Chemotherapy, Minneapolis, MN, October 1985.

PUBLISHED ABSTRACTS: (continued):

32. Rolston K and **Chandrasekar PH**: Group G streptococcal infections. 25th Interscience Conference on Antimicrobial Agents and Chemotherapy, Minneapolis, MN, October 1985.
33. **Chandrasekar PH**, Levine DP, Price L, and Unowsky J: Efficacy of coumermycin, teicoplanin in experimental endocarditis due to methicillin resistant Staphylococcus aureus. 25th Interscience Conference on Antimicrobial Agents and Chemotherapy, Minneapolis, MN, October 1986.
34. **Chandrasekar PH** and Crane LR: In vitro tests vs. clinical outcome in pseudomonal infection. Emergence of betalactam resistance despite synergy. 86th Annual Meeting of American Society for Microbiology, Washington DC, March 1986.
35. Palchaudhuri SP, Kumar R, Pal SC, and **Chandrasekar PH**: Epidemic of diarrhea in West Bengal, India due to ampicillin resistant Shiga bacillus. 86th Annual Meeting of American Society for Microbiology, Washington DC, March 1986.
36. Mehta R and **Chandrasekar PH**: Leprosy in a Laotian immigrant with G6PD deficiency. Epidemiological trend of leprosy in USA. Regional Meeting, American College of Physicians, Michigan Chapter and the Michigan Society of Internal Medicine, Traverse City, MI, September 1986.
37. Jelinek MT and **Chandrasekar PH**: Actinomyces odontolyticus septicemia following urethral instrumentation in a cancer patient. Regional Meeting, American College of Physicians, Michigan Chapter and the Michigan Society of Internal Medicine, Traverse City, MI, September 1986.
38. **Chandrasekar PH**, Price S, and Levine DP: Alternative agents to B-lactam/ vancomycin against methicillin resistant (MR-) and susceptible (MS-) staphylococci. 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, September-October 1986.
39. **Chandrasekar PH** and Mehta R: Spinal epidural abscess (EA) in intravenous drug abusers (IVDA). 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, September-October 1986.
40. **Chandrasekar PH**, Rybak MJ, and Albrecht LM: Retrospective analysis of vancomycin's adverse reactions in 135 patients. 87th Annual Meeting of American Society for Microbiology, Atlanta, GA, March 1987.
41. **Chandrasekar PH**, Sluchak J, Levine D, and Heyden J: Resistance development among staphylococci following exposure to sub-inhibitory concentrations of Paldimycin. 87th Annual Meeting of American Society for Microbiology, Atlanta, GA, March 1987.

PUBLISHED ABSTRACTS: (continued):

42. Gupta V and **Chandrasekar PH**: Rising trend in pulmonary tuberculosis at a Detroit City Hospital. Regional Meeting, American College of Physicians, Michigan Chapter and the Michigan Society of Internal Medicine, Traverse City, MI, September 1987.
43. Mehta R and **Chandrasekar PH**: Native valve Staphylococcus epidermidis endocarditis with fatal outcome. Regional Meeting, American College of Physicians, Michigan Chapter and the Michigan Society of Internal Medicine, Traverse City, MI, September 1987.
44. Rybak MJ, Albrecht LM, and **Chandrasekar PH**: Analysis of vancomycin nephrotoxicity. 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, NY, October 1987.
45. **Chandrasekar PH** and Sluchak J: Effect of clavulanic acid on betalactam activity against methicillin susceptible and resistant Staphylococcus aureus. 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, NY, October 1987.
46. **Chandrasekar PH** and Matthews M: Risk factors for HIV infection among parenteral drug abusers (PDA) in a low prevalence area. *Clinical Research* 35(6), A857, October 1987.
47. Gupta V and **Chandrasekar PH**: Rising trend in pulmonary tuberculosis at a Detroit City Hospital. Presented at the Annual Meeting of the American College of Physicians, New York, New York, March, 1988.
48. Ham SD, Roszler MH, **Chandrasekar PH**, and Darmody WR: Epidural abscess in intravenous drug abusers. Annual Meeting of the American Association of Neurological Surgeons, Toronto, Ontario, April 24-28, 1988.
49. Gobel JW, **Chandrasekar PH**, and Greville HW: Opportunistic versus non-opportunistic infection in HIV infected intravenous drug abusers. Annual Meeting of the American Thoracic Society, Las Vegas, Nevada, May, 1988.
50. **Chandrasekar PH** and Sluchak JA: Newer agents against Methicillin and/or gentamicin resistant and susceptible Staphylococcus aureus & Staphylococcus epidermidis. 88th Annual Meeting of American Society for Microbiology, Miami, Florida, May, 1988.
51. **Chandrasekar PH**, Sluchak JA, and Hayden JF: Influence of inoculum size and antibiotic concentration on post-antibiotic effect of quinolones and gentamicin against Pseudomonas aeruginosa. 88th Annual Meeting of American Society for Microbiology, Miami, Florida, May 1988.
52. **Chandrasekar PH**, Sluchak JA, and Zurack MR: Post-antibiotic effect: peptides & newer fluoroquinolones against methicillin resistant Staphylococcus aureus. 88th Annual Meeting of American Society for Microbiology, Miami, Florida, May, 1988.

PUBLISHED ABSTRACTS: (continued):

53. **Chandrasekar PH** and Mathews M: Risk factors for HIV infection among parenteral drug abusers (PDA) in a low prevalence area. Presented at the IV International Conference on AIDS, Stockholm, Sweden, June 12-16, 1988.
54. **Chandrasekar PH** and Sluchak JA: Methicillin resistant staphylococci: susceptibility to clavulanic acid (CA) plus betalactams and betalactamase quantitation. 89th Annual Meeting of American Society for Microbiology, New Orleans, Louisiana, May 1989.
55. **Chandrasekar PH** and Sluchak JA: Alternative agents against methicillin-resistant and susceptible Staphylococcus aureus and Staphylococcus epidermidis. 89th Annual Meeting of American Society for Microbiology, New Orleans, Louisiana, May 1989.
56. Norello C, Knapp T, Cronin S, and **Chandrasekar PH**: Nephrotoxicity in bone marrow transplant patients receiving aminoglycoside plus cyclosporine-A or aminoglycoside alone. 16th International Congress of Chemotherapy, Jerusalem, Israel, June 11-16, 1989.
57. **Chandrasekar PH** and Sluchak JA: In vitro efficacy of sulbactam vs clavulanic acid in combination with cefoperazone against cefoperazone susceptible and multiresistant gram-negative bacteria, 16th International Congress of Chemotherapy, Jerusalem, Israel, June 11-16, 1989.
58. Tsai YH and **Chandrasekar PH**: Fatal pseudomonal maltophilia bacteremia in a patient with leukemia. American College of Physicians, Michigan Chapter and the Michigan Society of Internal Medicine, Traverse City, Michigan, September, 1989.
59. Tsai YH and **Chandrasekar PH**: Infected chylothorax in a patient treated with radiotherapy for vertebral metastases from prostatic carcinoma. American College of Physicians, Michigan Chapter and the Michigan Society of Internal Medicine, Traverse City, Michigan, September, 1989.
60. Mandanas RA, Tsai YH, Chiou CY, and **Chandrasekar PH**: Infectious complications following bone marrow transplantation in autologous vs allogeneic marrow recipients. American College of Physicians, Michigan Chapter and the Michigan Society of Internal Medicine, Traverse City, Michigan, September, 1989.
61. Rudnick CA and **Chandrasekar PH**: A comparative study of community acquired gram-positive bacteremia in HIV (+) vs HIV (-) intravenous drug abusers. American College of Physicians, Michigan Chapter and the Michigan Society of Internal Medicine, Traverse City, Michigan, September, 1989.
62. Sanchez V, **Chandrasekar PH**, and Sobel JD: Diagnosing systemic candidiasis in neutropenic cancer patients using a candida antigen test. 90th Annual Meeting of the American Society for Microbiology, Anaheim, California, May 1990.

PUBLISHED ABSTRACTS: (continued):

63. **Chandrasekar PH**, Rolston KV, Sluchak JA, and Dorman NJ: In-vitro susceptibility of staphylococci in neutropenic cancer patients from two institutions. 90th Annual Meeting of the American Society for Microbiology, Anaheim, California, May 1990.
64. **Chandrasekar PH** and Sluchak JA: In-vitro efficacy of beta-lactamase inhibitors plus cefoperazone against multi-resistant Gram-negative bacilli. 90th Annual Meeting of the American Society for Microbiology, Anaheim, California, May 1990.
65. **Chandrasekar PH** and Sluchak JA: Newer vs older agents against staphylococci. 90th Annual Meeting of the American Society for Microbiology, Anaheim, California, May 1990.
66. Gorelick KJ, Schein RMH, MacIntyre NR, Emmanuel G, Bernard GR, and the XOMA Sepsis Study Group: Multicenter Trial of Antiendotoxin Antibody E5 in the Treatment of Gram-Negative Sepsis (GNS). Annual Meeting of the Society of Critical Care Medicine, California, May-June, 1990.
67. Martin MA, Wenzel RP, Gorelick KJ, and the Xoma Sepsis Study Group: Gram Negative Sepsis - Presentation, Therapy and Outcome in the 1980's. Annual Meeting of the Society of Critical Care Medicine, California, May-June, 1990.
68. Mandanas RA, Tsai YH, Chiou CY and **Chandrasekar PH**: Infectious complications following bone marrow transplantation in autologous vs allogeneic marrow recipients. 6th International Symposium on Infections in the Immunocompromised Host, Peebles, Scotland, June 1990.
69. Cheruku R, **Chandrasekar PH**, Ratanatharathorn V and Sensenbrenner L: Invasive Aspergillosis with concomitant bacterial/parasitic infections. Regional Meeting, American College of Physicians, Michigan Chapter and the Michigan Society of Internal Medicine, Traverse City, Michigan, October 1990.
70. **Chandrasekar PH** and Sluchak JA: In Vitro Efficacy of Quinolones Against Multi-resistant Aerobic Gram-Negative Bacillary Isolates from a Tertiary Care Institution. 91st Annual Meeting of the American Society for Microbiology, Dallas, Texas, May 1991.
71. **Chandrasekar PH** and Sluchak JA: In Vitro Susceptibility of Gram-Positive and Gram-Negative Bacteremic Isolates from Cancer Patients. 91 st Annual Meeting of the American Society for Microbiology, Dallas, Texas, May 1991.
72. MacIntyre NR, Emmanuel G, Wedel NI, Gorelick KJ, and the Xoma Sepsis Study Group. E5 Antibody Improves Outcome from Multi-Organ Failure in Survivors of Gram-Negative Sepsis. Annual Meeting of the Society of Critical Care Medicine, Washington, D.C., May 1991.

PUBLISHED ABSTRACTS: (continued):

73. Touchette MA, **Chandrasekar PH**, Milad MA, Edwards DJ. Differential Effects of Ketoconazole and Fluconazole on Phenytoin and Testosterone Concentrations in Man. Annual Meeting of the American College of Clinical Pharmacy, Minneapolis, Minnesota, August 1991.
74. **Chandrasekar PH**, Gatny C, Kruse JA and the Bone Marrow Transplant Team. Prospective, Randomized, Double-Blind Study of Antifungal Prophylaxis for Neutropenic Cancer Patients. Annual Meeting of the American College of Physicians, Traverse City.
75. Knoll-Vlachos S and **Chandrasekar PH**. Adult T-Cell Leukemia/Lymphoma In Detroit -A Non-Endemic Area for Human T Cell Lymphotropic Virus Type-I (HTLV-1). Annual Meeting of the American College of Physicians, Traverse City, Michigan, September, 1991.
76. Gatny CM, **Chandrasekar PH**, Crane LR and Visscher D. Extrapulmonary Pneumocystosis in an AIDS Patient on Aerosol Pentamidine Prophylaxis. Annual Meeting of the American College of Physicians, Traverse City, Michigan, September, 1991.
77. **Chandrasekar PH**, Sluchak J, Kruse JA and the Bone Marrow Transplantation Team. Quinolone Prophylaxis for Gut Decontamination during Bone Marrow Transplantation. Annual Meeting of the American College of Physicians, Traverse City, Michigan, September, 1991.
78. **Chandrasekar PH**, Gatny C, Kruse JA and the Bone Marrow Transplantation (BMT) Team. Reduction in Use of Amphotericin with Fluconazole Prophylaxis in Neutropenic Cancer Patients. Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, October, 1991.
79. **Chandrasekar PH**, Gatny C and Bone Marrow Transplantation Team. Reduction of Candidal Colonization with Fluconazole in Neutropenic Cancer Patients. Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, October, 1991.
80. **Chandrasekar PH**, Sluchak J. Cefoperazone Plus Sulbactam vs Cefoperazone Against Disseminated E. coli Infection in Neutropenic Mice. 92nd Annual Meeting of the American Society for Microbiology, New Orleans, Louisiana, May, 1992.
81. **Chandrasekar PH**, Sluchak J. Efficacy of Cefoperazone + Sulbactam (C + S) Against Cefoperazone Resistant E. coli Infection in Neutropenic Mice. 7th International Symposium on Infections in the Immunocompromised Host, Boulder, Colorado, June 1992. Michigan, September 1991.
82. Akhtar A, Eisenstadt J, Merline J, **Chandrasekar PH**, and BMT Unit, Harper and Children's Hospitals. Viral Infections in Patients Undergoing Bone Marrow Transplantation (BMT). 7th International Symposium on Infections in the Immunocompromised Host, Boulder, Colorado, June, 1992.

PUBLISHED ABSTRACTS: (continued):

83. Lerner SA, Levine DP, McNeil P, Rybak MJ, **Chandrasekar PH**, Albrecht L, and Schwan S. Blinded Comparative Study of Teicoplanin vs. Vancomycin for Gram-Positive Coccal Bacteremia: Failures of Therapy with Teicoplanin in Conventional Doses. VIIth International Symposium on Staphylococci and Staphylococcal Infections, Stockholm, Sweden, July, 1992,
84. Alangaden G, Shearer C, **Chandrasekar PH**, and BMT Team, Detroit Medical Center, Wayne State University School of Medicine. Fungemia Among Bone Marrow Transplant (BMT) Recipients, 1989-1991. Effect of Low-Dose Fluconazole Prophylaxis. Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, California, October, 1992.
85. Shearer C, **Chandrasekar PH** and BMT Team, Detroit Medical Center, Wayne State University School of Medicine, Detroit, MI. Cutaneous Alternariosis During Allogeneic Bone Marrow Transplantation (BMT). American College of Physicians, 38th Annual Michigan Scientific Meeting, Grand Traverse Village, Michigan, October, 1992.
86. Naik H, **Chandrasekar PH** and BMT Team, Detroit Medical Center, Wayne State University School of Medicine, Detroit, MI. Multiple Causes of Diarrhea During Allogeneic Bone Marrow Transplantation (BMT). American College of Physicians, 38th Annual Michigan Scientific Meeting, Grand Traverse Village, Michigan, October, 1992.
87. Naik H, **Chandrasekar PH** and BMT Team, Detroit Medical Center, Wayne State University School of Medicine, Detroit, MI. Successful Treatment with Foscarnet Against Acyclovir-Resistant Herpes Simplex Virus-I (HSV-1) Infection During Allogeneic Bone Marrow Transplantation (BMT). American College of Physicians, 38th Annual Michigan Scientific Meeting, Grand Traverse Village, Michigan, October, 1992.
88. Gajewski LK, Bailey EM, Brown P, and **Chandrasekar PH**. Determination of the Need for a Prospective DUE of Intravenous Immune Globulin at the Detroit Medical Center. 27th Annual American Society for Hospital Pharmacists, Orlando, Florida, December, 1992.
89. Khaliq Y, Bailey EM, Alangaden G, **Chandrasekar PH**. Effect of three dosage levels of fluconazole on fungal colonization in bone marrow transplant patients. American College of Clinical Pharmacy, 1993 Winter Practice and Research Forum, Ft. Lauderdale, Florida, February, 1993.
90. Molinari JA, **Chandrasekar PH**. Reemergence of Mycobacterium Tuberculosis Infection as a Major Occupational Risk for Health Professionals. Second International Workshop on the Oral Manifestations of HIV Infection, San Francisco, January 31 - February 3, 1993.
91. Sluchak JA, **Chandrasekar PH**. Bacterial Inoculum Size and Natural Course of Infection with *E. coli* and with *Pseudomonas aeruginosa* in a Neutropenic Mouse Model. 93rd Annual Meeting of the American Society for Microbiology, Atlanta, GA, May, 1993.

PUBLISHED ABSTRACTS: (continued):

92. Sluchak JA, **Chandrasekar PH**. Comparative Activities of Sulbactam, Clavulanic Acid or Tazobactam plus Cefoperazone against Multi-resistant, Aerobic Gram-Negative Bacilli. 93rd Annual Meeting of the American Society for Microbiology, Atlanta, GA, May, 1993.
93. Weinmann AJ, **Chandrasekar PH**, BMT Team. Mycobacteria in Bone Marrow Transplantation (BMT). Annual Meeting of the Infectious Diseases Society of America, New Orleans, LA, October, 1993.
94. **Chandrasekar PH**, Weinmann AJ, Shearer CJ. Autopsy-identified Infections In Bone Marrow Transplant (BMT) Recipients. Annual Meeting of the Infectious Diseases Society of America, New Orleans, LA, October, 1993.
95. Thompson E, Akhtar A, **Chandrasekar PH**, Bone Marrow Transplantation Team. Reduced Frequency of Administration of Ganciclovir for the Prevention of Cytomegalovirus (CMV) Infection in Bone Marrow Transplantation (BMT). 8th International Symposium on Infections in the Immunocompromised Host, Davos, Switzerland, June, 1994.
96. **Chandrasekar PH**, Sweet A, Bone Marrow Transplant Team. Prospective, Randomized, Double-Blinded Study of Efficacy of Cefoperazone Plus Sulbactam vs Ceftazidime in the Empiric Treatment of Febrile Neutropenic Patients. 8th International Symposium on Infections in the Immunocompromised Host, Davos, Switzerland, June, 1994.
97. Frey MJ, **Chandrasekar PH**, Bone Marrow Transplant Team. International Survey on Routine Screening Tests for Detection of Infection Prior to Bone Marrow Transplantation (BMT). 8th International Symposium on Infections in the Immunocompromised Host, Davos, Switzerland, June, 1994.
98. **Chandrasekar PH**. Tuberculosis in Cancer/Transplant Patients. Tuberculosis Workshop) Satellite Symposium. 8th International Symposium on Infections in the Immunocompromised Host, Davos, Switzerland, June, 1994.
99. Kaptur C, Flanagan E, Bartley J, Lesperance M, **Chandrasekar PH**, Lundstrom T. Fungemias in Bone Marrow Transplant Patients in the Fluconazole Prophylaxis Era. 32nd Annual Meeting of the Infectious Diseases Society of America, Orlando, Florida, October 1994.
100. Brooks JV, **Chandrasekar PH**, Crane LR. Primary Central Nervous System (CNS) Lymphoma in AIDS. American Federation for Clinical Research, San Diego, California, May 1995.
101. **Chandrasekar PH**, Thompson E, Sivan C, Kraut M. Prospective evaluation of skin test for tuberculosis (PPD) in patients with head/neck or lung malignancy. 33rd Annual Meeting of the Infectious Diseases Society of America, San Francisco, California, September, 1995.

PUBLISHED ABSTRACTS: (continued):

102. Momin F, Khouilani M, Cherednikova L, **Chandrasekar PH**, and BMT Team. Toxoplasmosis in bone marrow transplantation (BMT). 33rd Annual Meeting of the 100.
103. Brooks JV, **Chandrasekar PH**, Crane LR. Primary Central Nervous System (CNS) Lymphoma in AIDS. American Federation for Clinical Research, San Diego, California, May 1995.
104. **Chandrasekar PH**, Thompson E, Sivan C, Kraut M. Prospective evaluation of skin test for tuberculosis (PPD) in patients with head/neck or lung malignancy. 33rd Annual Meeting of the Infectious Diseases Society of America, San Francisco, California, September, 1995.
105. Momin F, Khouilani M, Cherednikova L, **Chandrasekar PH**, and BMT Team. Toxoplasmosis in bone marrow transplantation (BMT). 33rd Annual Meeting of the Infectious Diseases Society of America, San Francisco, California, September, 1995.
106. Abbas M, **Chandrasekar PH**, BMT Team. Respiratory syncytial virus (RSV) In a bone marrow transplant (BMT) Unit, Winter, '94-'95. 33rd Annual Meeting of the Infectious Diseases Society of America, San Francisco, California, September 1995.
107. Lundstrom TS, Fairfax M, Vazquez JA, **Chandrasekar PH**, Abella S, Kasten- Sportes C. *Phialophora verrucosa* (PV) Causing Fatal Pulmonary Hemorrhage in a Bone Marrow Transplant (BMT) Patient. 33rd Annual Meeting of the Infectious Diseases Society of America, San Francisco, California, September 1995.
108. **Chandrasekar PH**, Prior L, Kraut M. Prospective Evaluation of Skin Test for Tuberculosis (PPD) in Patients with Head/Neck or Lung Malignancy. 9th International Symposium on Infections in the Immunocompromised Host, Assisi, Italy, June 1996.
109. Brohi S, **Chandrasekar PH**, and BMT Team. Infectious Complications in Recipients of Bone Marrow from Unrelated Donors. 9th International Symposium on Infections in the Immunocompromised Host, Assisi, Italy, June 1996.
110. Brohi S, **Chandrasekar PH**, and BMT Team. Twice Weekly Ganciclovir Prophylaxis against Cytomegalovirus (CMV) Disease in Allogeneic Bone Marrow Transplantation (BMT) Recipients. 9th International Symposium on Infections in the Immunocompromised Host, Assisi, Italy, June 1996.
111. Hathorn J, **Chandrasekar PH**, Baird I, Arnow P, Waskin H, and the Cefepime FN Study Group. Double-blind comparison of Cefepime vs Ceftazidime to Treat Febrile Neutropenia. 36th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, September 1996.
112. Villanueva A, Khierbek S., **Chandrasekar PH**. Parvovirus B-19 Infection in a Patient with Sickle Cell Disease Presenting as Pain and Aplastic Crises: A Case Report. American College of Physicians Annual Meeting, Traverse City, Michigan, September, 1996.

PUBLISHED ABSTRACTS: (continued):

113. Saker S, Puklin JE, **Chandrasekar PH**. Fatal Aspergillosis with Endophthalmitis in an Allogeneic Marrow Recipient. American College of Physicians Annual Meeting, Grand Rapids, Michigan, May 1997.
114. Manavathu EK, Cutright JL, **Chandrasekar PH**. In-Vitro Susceptibility of Itraconazole-resistant Isolates of *Aspergillus fumigatus* to Voriconazole. 8th European Congress of Clinical Microbiology and Infectious Diseases, Lausanne, Switzerland, May 25-28, 1997.
115. Diwakaran H, Saravanan SM, **Chandrasekar PH**. Angioimmunoblastic Lymphadenopathy with Dysproteinemia in a patient with AIDS: A Case Report. American College of Physicians Annual Meeting, Traverse City, Michigan, September 1997.
116. Manavathu EK, Cutright JL, **Chandrasekar PH**. Organism-Dependent Fungicidal Activity of Azoles. 35th Annual Meeting of the Infectious Diseases Society of America, San Francisco, California, September 1997.
117. Abraham OC, Manavathu EK, **Chandrasekar PH**. In-Vitro Activities of Voriconazole, Itraconazole and Amphotericin B against *Aspergillus* species. 35th Annual Meeting of the Infectious Diseases Society of America, San Francisco, California, September 1997.
118. Manavathu EK, Cutright JL, **Chandrasekar PH**. A Comparative Study of the In-Vitro Susceptibility of Amphotericin B-Resistant Isolates of *Aspergillus fumigatus* to Voriconazole and Itraconazole. 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 28 - October 1, 1997.
119. Manavathu EK, Cutright JL, Dimmock JR, **Chandrasekar PH**. In Vitro and In Vivo Susceptibility of *Aspergillus fumigatus* to a New Conjugated Styrl Ketone. In: Programs and Abstracts of the 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 28 - October 1, 1997.
120. Gnann J, Tyring S, Burdge D, **Chandrasekar PH**, Wallace M, Beutner K, Weiss H, Soong S, Sherrill L, Laughlin C, Whitley R, and the CASG Herpes Zoster Study Group. Oral Antiviral Therapy for Herpes Zoster in Immunocompromised Patients: Sorivudine vs. Acyclovir. In: Programs and Abstracts of the 35th Annual Meeting of the Infectious Diseases Society of America, San Francisco, California, September 1997.
121. Manavathu EK, Vazquez JA, **Chandrasekar PH**. Reduced Susceptibility of *Aspergillus fumigatus* to Itraconazole Due to Decreased Intracellular Accumulation of the Antifungal Agent. In: Programs and Abstracts of the 98th General Meeting of the American Society for Microbiology, Atlanta, Georgia, May 1998.

PUBLISHED ABSTRACTS: (continued):

122. Pulimood S, Alangaden G, **Chandrasekar PH**. Changing Epidemiology of Candidemia at a Tertiary Care Institution. In: Programs and Abstracts of the 10th International Symposium on Infections in the Immunocompromised Host Society, Davos, Switzerland, June 21-24, 1998.
123. Pulimood S, Alanagaden G, **Chandrasekar PH**. Candidemia Due to Multiple Candidal Species at a Tertiary Care Institution. In: Programs and Abstracts of the 10th International Symposium on Infections in the Immunocompromised Host Society, Davos, Switzerland, June 21-24, 1998.
124. Ucar E, Karanes C, Abella S, **Chandrasekar PH**. Trends in Bacteremia Among Cancer/Marrow Transplant Patients During 1991-1995. In: Programs and Abstracts of the 10th International Symposium on Infections in the Immunocompromised Host Society, Davos, Switzerland, June 21-24, 1998.
125. Manavathu E, Cutright J, **Chandrasekar PH**. In Vitro and In Vivo Resistance to Amphotericin B of a Mutant Isolate of *Aspergillus fumigatus*. In: Programs and Abstracts of the 10th International Symposium on Infections in the Immunocompromised Host Society, Davos, Switzerland, June 21-24, 1998.
126. Kumar A, Alangaden GJ, Akhtar A, Karanes C, Abella S, Dansey R, Klein J, Baynes R, **Chandrasekar PH**. Significance of *Aspergillus* in Clinical Specimens from Cancer Patients at a Tertiary Care Center. In: Programs and Abstracts of the 10th International Symposium on Infections in the Immunocompromised Host Society, Davos, Switzerland, June 21-24, 1998.
127. Bowden R, **Chandrasekar PH**, White M, J-A van Burik J, Wingard J and the Multicenter *Aspergillus* Study Group. A Double-Blind, Randomized, Controlled Trial of Amphotericin B (ABCD) vs Amphotericin B (AmB) for treatment of invasive aspergillosis in immunocompromised patients. In: Programs and Abstracts of the 10th International Symposium on Infections in the Immunocompromised Host Society, Davos, Switzerland, June 21-24, 1998.
128. Manavathu EK, Dimmock JR, Vashishtha SC, Cutright JL, and **Chandrasekar PH**. Proton Pumping ATPase Directed Fungicidal Activity of a Novel Conjugated Styryl Ketone. In: Programs and Abstracts of the 38th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 24-27, 1998.
129. Kanno M, **Chandrasekar PH**, Alanagaden G. Cytomegalovirus (CMV) disease in non-transplant recipients and non-HIV patients. IN: Programs and Abstracts of the 36th Annual Meeting of the Infectious Diseases Society of America, Denver, Colorado, November 1998.

PUBLISHED ABSTRACTS: (continued):

130. Manavathu EK, Abraham OC, Cutright JL and **Chandrasekar PH**. Isolation and In Vitro Susceptibility To Amphotericin B (AMB), Itraconazole (ITZ) and SCH56592 (SCH) of Voriconazole (VCZ)-resistant Laboratory Isolates of *Aspergillus fumigatus*. 99th General Meeting of the American Society of Microbiology, Chicago, Illinois, May 30-June 3, 1999
131. Manavathu EK, Cutright JL and **Chandrasekar PH**. A Comparative Study of the In-Vitro Susceptibility of *Aspergillus* Species to SCH56592 (SCH), Amphotericin B (AMB), Itraconazole (ITZ) and Voriconazole (VCZ). 99th General Meeting of the American Society of Microbiology, Chicago, Illinois, May 30-June 3, 1999.
132. Manavathu EK, Dimmock JR, **Chandrasekar PH**. H⁺-ATPase Dependent Activity of a Novel Conjugated Styryl Ketone Against *Cryptococcus neoformans*. In: Programs and Abstracts of the 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, September 26-29, 1999.
133. Manavathu EK, Cutright JL and **Chandrasekar PH**. Species Diversity and In Vitro Antifungal Susceptibility of Clinical Isolates of *Aspergillus* Obtained in a Medical Center from January 1994 to December 1998. In: Programs and Abstracts of the 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, September 26-29, 1999.
134. Wahiduzzaman M, **Chandrasekar PH**, Alangaden GJ. High Frequency of Gram-negative Bacterial Pneumonia in Bone Marrow/Stem Cell Transplant (BMT) Recipients with Graft-vs-Host Disease (GVHD) and Pulmonary Aspergillosis. IN: Programs and Abstracts of 37th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA, November 1999.
135. Abraham OC, Klein J, Chalasani G, Cassells L, Dansey R, Abella S, Karanes C, Peters W, Baynes R, **Chandrasekar PH**. Infectious Complications in Women Undergoing Autologous Peripheral Blood Progenitor Cell Transplantation (PBPCT) for Breast Cancer. IN: Programs and Abstracts of 37th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA, November 1999.
136. Hidalgo JA, Alangaden GJ, Akins RA, Abrams GW, Elliott D, Puklin J, **Chandrasekar PH**, Vazquez JA. Diagnosis of Fungal Endophthalmitis by Detection of *Candida albicans* DNA in Vitreous Specimens Using a Species-Specific PCR. IN: Programs and Abstracts of 37th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA, November 1999.
137. Winston DJ, Yeager AM, **Chandrasekar PH**, Snyderman D, Peterson FB and the Valaciclovir Study Group. Randomized Comparison for Prophylaxis of CMV Disease and Other Complications after Allogeneic Bone Marrow Transplantation. 2nd International Conference on Transplant Infectious Diseases, Stockholm, Sweden, May 2000.

PUBLISHED ABSTRACTS: (continued):

138. Jamma K, **Chandrasekar PH**, Karanes C, Klein J, Cassells L, Dansey R, Abella S, Peters W, Baynes R, Alangaden GJ. Spectrum of *Clostridium difficile* Diarrhea during Stem Cell Transplants (SCT). IN: Programs and Abstracts of the 11th International Symposium on Infections in the Immunocompromised Host. Halifax, Nova Scotia, June 18-21, 2000.
139. **Chandrasekar PH**, Cutright JL and Manavathu EK. Antifungal Susceptibility, Frequency of Isolation and Species Diversity of Clinical Isolates at Detroit Medical Center Over a 6-Year Period. IN: Programs and Abstracts of the 11th International Symposium on Infections in the Immunocompromised Host, Halifax, Nova Scotia, June 18-21, 2000.
140. Manavathu EK, Krishnan S, Cutright JL, and **Chandrasekar PH**. A Comparative Study of the In Vitro Susceptibility of *Aspergillus fumigatus* to Antifungal Agents Individually and in Combinations. IN: Programs and Abstracts of the 11th International Symposium on Infections in the Immunocompromised Host, Halifax, Nova Scotia, June 18-21, 2000.
141. Chilukuri S, Alangaden G, Karanes C, Klein J, Cassells L, Dansey R, Abella S, Peters W, Baynes R, **Chandrasekar PH**. Antifungal Chemoprophylaxis in Bone Marrow/Stem Cell Transplantation: An International Survey. IN: Programs and Abstracts of the 11th International Symposium on Infections in the Immunocompromised Host. Halifax, Nova Scotia, June 18-21, 2000.
142. Moosa MYS, Alangaden GJ, Manavathu E, Cutright JL and **Chandrasekar PH**. Does emergence of resistance to amphotericin B during treatment for invasive aspergillosis contribute to a poor outcome? IN: Programs and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 17-20, 2000.
143. Manavathu EK, Dimmock JR, Cutright JL and **Chandrasekar PH**. Proton-translocating-ATPase-targeted antifungal activity of a novel conjugated styryl ketone: kinetics of inhibition of *Candida albicans* H⁺-ATPase. IN: Programs and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 17-20, 2000. Abstract No. 1095.
144. Manavathu EK, Krishnan S, Cutright JL and **Chandrasekar PH**. A comparative study of the in vitro susceptibility of *Aspergillus fumigatus* to antifungal agents individually and in combinations by the fractional inhibitory concentration index, tetrazolium reduction and radiometric assays. IN: Programs and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 17-20, 2000. Abstract No. 931.

PUBLISHED ABSTRACTS: (continued):

145. **Chandrasekar PH**, Cutright JL, and Manavathu EK. Antifungal susceptibility, frequency of isolation and species diversity of clinical isolates of *Aspergillus* at the Detroit Medical Center over a 6-year period (1994-1999). IN: Programs and Abstracts of the 11th International Symposium on Infections in the Immunocompromised Host. Halifax, Nova Scotia, Canada. June 19-21, 2000.
146. Alangaden G.J, Thompson E, Yoon S, Akins R, **Chandrasekar PH**, Vazquez J. Diagnosis of invasive fungal infections by detection of fungal DNA in clinical specimens using a species-specific PCR. IN: Programs and Abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America, September 7-10, 2000, New Orleans, Louisiana. (Abstract #273)
147. Alangaden G.J, Jamma K, **Chandrasekar PH**, Karanes C, Klein J, Cassells L, Dansey R, Abella S, Peters W, Baynes R. Clostridium difficile associated diarrhea during hematopoietic stem cell transplantation. IN: Programs and Abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America, September 7-10, 2000, New Orleans, Louisiana. (Abstract #395).
148. Manavathu EK, Baskaran I, Alangaden GJ and **Chandrasekar PH**. Molecular characterization of the P450-dependent lanosterol demethylase gene from clinical isolates of *Aspergillus fumigatus*. IN: Programs and Abstracts of the 101st General Meeting of the American Society for Microbiology, May 20-24, 2001, Orlando, Florida, Abstract F-20.
149. Manavathu EK, Baskaran I, Alangaden GJ and **Chandrasekar PH**. Differential susceptibility of itraconazole resistant *Aspergillus fumigatus* isolates to triazoles. IN: Programs and Abstracts of the 101st General Meeting of the American Society for Microbiology, May 20-24, 2001, Orlando, Florida, Abstract A-18.
147. Varanasi NL, Baskaran I, Alangaden GJ, **Chandrasekar PH**, and Manavathu EK. Novel effect of voriconazole on conidiation and pigmentation of *Aspergillus* species. IN: Programs and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001, Chicago, Illinois. Abstract J-816.
148. Manavathu EK, Baskaran I, Alangaden GJ and **Chandrasekar PH**. Molecular characterization of laboratory isolates of *Aspergillus fumigatus* showing reduced susceptibility to voriconazole. IN: Programs and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001, Chicago, Illinois. Abstract J-817.
149. Ramesh MS, Baskaran I, Ganesan LT, Manavathu EK and **Chandrasekar PH**. Post antifungal effect of older and newer antifungal agents on *Aspergillus fumigatus* and *Candida albicans*. IN: Programs and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001, Chicago, Illinois. Abstract J-105.

PUBLISHED ABSTRACTS: (continued):

150. Varanasi NL, Baskaran I, Alangaden GJ, Thomas PA, **Chandrasekar PH**, Manavathu EK. In vitro susceptibility and azole resistance among clinical and laboratory-selected isolates of *Aspergillus flavus* obtained from three continents. IN: Programs and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001, Chicago, Illinois. Abstract J-271.
151. Cutright JL, Manavathu EK and **Chandrasekar PH**. In vivo virulence of laboratory-selected azole-resistant *Aspergillus fumigatus* in a murine pulmonary aspergillosis model. IN: Programs and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001, Chicago, Illinois. Abstract J-1613.
152. Manavathu EK, Ganesan LT, Cutright JL and **Chandrasekar PH**. In vitro antifungal activity of voriconazole in two-drug combination with Micafungin, Caspofungin and Amphotericin B. IN: Programs and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001, Chicago, Illinois. Abstract J-125.
153. Winston DJ, Maziarz R, **Chandrasekar PH**, Bhimer J, et al. Long-term antifungal prophylaxis in allogeneic bone marrow transplant patients: A multicenter, randomized trial of intravenous/oral itraconazole vs. intravenous/oral fluconazole. American Society Hematology, December 2001.

Abstract List Discontinued after 2001